Atlas Trials

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Clinical trial NCT02726568 · UNKNOWN

Trial details

NCT number
NCT02726568
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung CancerBrain Metastases
Start date
2016-03-01
Primary completion
2021-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.